Test ID: ESTRDP SP

Estradiol and Estrone by LC-MS/MS, Serum/Plasma

Test Overview

Clinical Utility

Simultaneous high-sensitivity determination of serum estrone and estradiol levels. Situations requiring either higher sensitivity estradiol measurement, estrone measurement, or both, including

As part of the diagnosis and workup of precocious and delayed puberty
As part of the diagnosis and workup of suspected disorders of sex steroid metabolism, (eg, aromatase deficiency and 17 alpha-hydroxylase deficiency)
As an adjunct to clinical assessment, imaging studies, and bone mineral density measurement in the fracture risk assessment of postmenopausal women
Monitoring low-dose female hormone replacement therapy in postmenopausal women
Monitoring antiestrogen therapy (eg, aromatase inhibitor therapy)

In conjunction with luteinizing hormone measurements, monitoring of estrogen replacement therapy in hypogonadal premenopausal women.
Evaluation of feminization, including gynecomastia, in males.
Diagnosis of estrogen-producing neoplasms.

Method

Liquid chromatography-tandem mass spectrometry (LC-MS/MS)

Result Included

Estrone; Estradiol

Aliases/Synonyms

E1; E2; Estrogens

Specimen

Specimen Type

Serum
Plasma

Containers

Preferred Containers

SST (Gold Top)

Acceptable Containers

Na Heparin (Green Top); Lithium Heparin (Green Top)

Volume

Sample Volume

1.0 mL (preferred)

Minimum Volume

0.5 mL

Collection & Handling

Handling Information

Separate serum or plasma from cells within 2 hours of collection.

Stability

Ambient	Refrigerated	Frozen
1 day	7 days	180 days

Rejection Criteria

Criteria	Specification
Hemolysis	Present

Performance & Interpretation

Turnaround Time

8 days

Results

Estradiol

pmol/L

Female
≤14 days: ≤ 242
Stage I (> 14 days and prepubertal): ≤ 74
Stage II: ≤ 88
Stage III: ≤ 221
Stage IV: 55 - 312
Stage V: 55 - 1287
≥ 19 years
Follicular phase: 55 - 368
Luteal phase: 257 - 1103
Postmenopausal: ≤ 55
Male
≤ 14 days: ≤ 194
Stage I (> 14 days and prepubertal): ≤ 48
Stage II: ≤ 59
Stage III: ≤ 96
Stage IV: ≤ 140
Stage V: 37 - 147
≥ 19 years: 37-147

Comment

Limit of Quantitation: 5 pmol/L
Estrone

pmol/L

Female
≤ 14 days: Not Established
Stage I: (> 14 days and prepubertal): ≤ 108
Stage II: 37 - 122
Stage III: 55 - 160
Stage IV: 59 - 285
Stage V: 63 - 741
≥ 19 years
Premenopausal: 63 - 741
Postmenopausal: 25 - 148
Male:≤ 14 days: Not Established
Stage I: (> 14 days and prepubertal): ≤ 60
Stage II: ≤ 82
Stage III: 37 - 93
Stage IV: 37 - 171
Stage V: 37 - 222
≥ 19 years: 37-222

Comment

Upper reporting Limit: 10,000
Lower reporting Limit: 6.0

Referral Location

Canada

Interface & Setup

HL7 Interface Codes

Order Code	Result Name	Result Codes	Units
ESTRDP SP Units	Estradiol	64548	pmol/L
	Estrone	64527	pmol/L

Test Version

Last Updated

2026-01-19